HUP0104111A2 - Stabil, koncentrált inzulinkészítmény pulmonáris bejuttatáshoz - Google Patents
Stabil, koncentrált inzulinkészítmény pulmonáris bejuttatáshozInfo
- Publication number
- HUP0104111A2 HUP0104111A2 HU0104111A HUP0104111A HUP0104111A2 HU P0104111 A2 HUP0104111 A2 HU P0104111A2 HU 0104111 A HU0104111 A HU 0104111A HU P0104111 A HUP0104111 A HU P0104111A HU P0104111 A2 HUP0104111 A2 HU P0104111A2
- Authority
- HU
- Hungary
- Prior art keywords
- pulmonary delivery
- insulin
- insulin preparations
- stable concentrated
- concentrated insulin
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 8
- 102000004877 Insulin Human genes 0.000 title abstract 4
- 108090001061 Insulin Proteins 0.000 title abstract 4
- 229940125396 insulin Drugs 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title abstract 3
- 230000002685 pulmonary effect Effects 0.000 title abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
- -1 Zn2 ions Chemical class 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
A tal lm ny olyan vizes inzulinkészítményre vonatkozik, amely 6-15 mMhum n inzulint, vagy analógot, vagy sz rmazékot, a klorid-iontól ésacet tiontól eltérő b rmilyen anionból legfeljebb 10 mM mennyiséget,hat inzulin molekul nként 2-5 Zn2-iont, és hat inzulin molekul nkéntlegal bb 3 fenolos molekul t tartalmaz. A tal lm ny szerintikészítmény alkalmas diabeteses betegek pulmon ris úton t"rténőbeadagol sra. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199801327 | 1998-10-16 | ||
| PCT/DK1999/000556 WO2000023098A1 (en) | 1998-10-16 | 1999-10-15 | Stable concentrated insulin preparations for pulmonary delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0104111A2 true HUP0104111A2 (hu) | 2002-04-29 |
| HUP0104111A3 HUP0104111A3 (en) | 2002-05-28 |
Family
ID=8103620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0104111A HUP0104111A3 (en) | 1998-10-16 | 1999-10-15 | Stable concentrated insulin preparations for pulmonary delivery |
Country Status (22)
| Country | Link |
|---|---|
| EP (2) | EP1121144B1 (hu) |
| JP (1) | JP4212240B2 (hu) |
| KR (1) | KR100617286B1 (hu) |
| CN (1) | CN1210058C (hu) |
| AT (2) | ATE277630T1 (hu) |
| AU (1) | AU758146B2 (hu) |
| BR (1) | BR9914585A (hu) |
| CA (1) | CA2346969A1 (hu) |
| CZ (1) | CZ20011134A3 (hu) |
| DE (2) | DE69920767T2 (hu) |
| DK (2) | DK1121144T3 (hu) |
| ES (2) | ES2177323T3 (hu) |
| HU (1) | HUP0104111A3 (hu) |
| IL (2) | IL142011A0 (hu) |
| NO (1) | NO323365B1 (hu) |
| PL (1) | PL197504B1 (hu) |
| PT (2) | PT1121144E (hu) |
| RU (1) | RU2218935C2 (hu) |
| TW (1) | TWI223597B (hu) |
| UA (1) | UA65636C2 (hu) |
| WO (1) | WO2000023098A1 (hu) |
| ZA (1) | ZA200102105B (hu) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5783556A (en) * | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| NZ519403A (en) * | 2001-06-21 | 2005-03-24 | Pfizer Prod Inc | Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels |
| ES2360182T3 (es) * | 2002-05-07 | 2011-06-01 | Novo Nordisk A/S | Formulaciones solubles que comprenden insulina monomérica e insulina acilada. |
| DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| JP4607010B2 (ja) | 2003-02-28 | 2011-01-05 | 中外製薬株式会社 | タンパク質含有安定化製剤 |
| WO2004080480A1 (en) * | 2003-03-11 | 2004-09-23 | Novo Nordisk A/S | Pharmaceutical preparations comprising acid-stabilised insulin |
| EP2264065B1 (en) | 2003-08-05 | 2017-03-08 | Novo Nordisk A/S | Novel insulin derivatives |
| CN101389650B (zh) | 2005-12-28 | 2012-10-10 | 诺沃-诺迪斯克有限公司 | 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法 |
| EP2049149B1 (en) | 2006-07-31 | 2015-04-15 | Novo Nordisk A/S | Pegylated extended insulins |
| JP5864834B2 (ja) | 2006-09-22 | 2016-02-17 | ノボ・ノルデイスク・エー／エス | プロテアーゼ耐性のインスリンアナログ |
| US20100120660A1 (en) * | 2007-04-30 | 2010-05-13 | Per Balschmidt | Highly concentrated insulin solutions and compositions |
| US9387176B2 (en) | 2007-04-30 | 2016-07-12 | Novo Nordisk A/S | Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein |
| JP5552046B2 (ja) * | 2007-06-13 | 2014-07-16 | ノボ・ノルデイスク・エー／エス | インスリン誘導体を含有する薬学的製剤 |
| JP5762001B2 (ja) | 2008-03-14 | 2015-08-12 | ノボ・ノルデイスク・エー／エス | プロテアーゼ安定化インスリンアナログ |
| PT2254906T (pt) | 2008-03-18 | 2017-01-03 | Novo Nordisk As | Análogos de insulina acilados, estabilizados contra proteases |
| TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| AU2011235959C1 (en) * | 2008-06-13 | 2013-10-10 | Eli Lilly And Company | PEGylated insulin lispro compounds |
| KR101820024B1 (ko) | 2008-10-17 | 2018-01-18 | 사노피-아벤티스 도이칠란트 게엠베하 | 인슐린과 ｇｌｐ－1 효능제의 병용물 |
| US9603904B2 (en) | 2008-10-30 | 2017-03-28 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| ES2534191T3 (es) | 2009-11-13 | 2015-04-20 | Sanofi-Aventis Deutschland Gmbh | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
| HUE037735T2 (hu) | 2009-11-13 | 2018-09-28 | Sanofi Aventis Deutschland | DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény |
| BR112013004756B1 (pt) | 2010-08-30 | 2020-04-28 | Sanofi Aventis Deutschland | uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2 |
| RU2013123515A (ru) | 2010-10-27 | 2014-12-10 | Ново Нордиск А/С | Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| RU2650616C2 (ru) | 2011-08-29 | 2018-04-16 | Санофи-Авентис Дойчланд Гмбх | Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| CA2870313A1 (en) | 2012-04-11 | 2013-10-17 | Novo Nordisk A/S | Insulin formulations |
| MX2015006997A (es) * | 2012-12-26 | 2015-09-23 | Wockhardt Ltd | Composicion farmaceutica. |
| DK2983697T3 (en) | 2013-04-03 | 2019-02-25 | Sanofi Sa | TREATMENT OF DIABETES MELLITUS WITH LONG-EFFECTIVE FORMULATIONS OF INSULIN |
| EP2991672A1 (en) | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
| AU2014333979B2 (en) | 2013-10-07 | 2018-02-15 | Novo Nordisk A/S | Novel derivative of an insulin analogue |
| JP6970615B2 (ja) | 2014-12-12 | 2021-11-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン／リキシセナチド固定比処方 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
| CN110087674B (zh) | 2016-12-16 | 2023-01-03 | 诺和诺德股份有限公司 | 含胰岛素的药物组合物 |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| CN114096269B (zh) * | 2019-07-12 | 2024-06-11 | 诺和诺德股份有限公司 | 高浓度胰岛素制剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI78616C (fi) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
| US5506203C1 (en) * | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
| US5474978A (en) * | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US5504188A (en) * | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
| ATE369146T1 (de) * | 1996-06-20 | 2007-08-15 | Novo Nordisk As | Insulinpreparation mit mannitol |
| ATE220555T1 (de) * | 1997-03-20 | 2002-08-15 | Novo Nordisk As | Verfahren zur herstellung eines therapeutischen puders durch copräzipitation von insulin und einem absorptionsverstärker |
| AU6611998A (en) * | 1997-03-20 | 1998-10-20 | Novo Nordisk A/S | Therapeutic powder formulation for pulmonary administration, containing crystalline insulin |
-
1999
- 1999-10-15 DE DE69920767T patent/DE69920767T2/de not_active Expired - Lifetime
- 1999-10-15 CN CNB998122084A patent/CN1210058C/zh not_active Expired - Fee Related
- 1999-10-15 UA UA2001042148A patent/UA65636C2/uk unknown
- 1999-10-15 HU HU0104111A patent/HUP0104111A3/hu unknown
- 1999-10-15 ES ES99948725T patent/ES2177323T3/es not_active Expired - Lifetime
- 1999-10-15 ES ES01126054T patent/ES2228728T3/es not_active Expired - Lifetime
- 1999-10-15 DK DK99948725T patent/DK1121144T3/da active
- 1999-10-15 AT AT01126054T patent/ATE277630T1/de not_active IP Right Cessation
- 1999-10-15 AT AT99948725T patent/ATE218364T1/de not_active IP Right Cessation
- 1999-10-15 RU RU2001113271/14A patent/RU2218935C2/ru not_active IP Right Cessation
- 1999-10-15 DE DE69901726T patent/DE69901726T2/de not_active Expired - Lifetime
- 1999-10-15 PL PL347210A patent/PL197504B1/pl not_active IP Right Cessation
- 1999-10-15 KR KR1020017004702A patent/KR100617286B1/ko not_active IP Right Cessation
- 1999-10-15 JP JP2000576871A patent/JP4212240B2/ja not_active Expired - Fee Related
- 1999-10-15 EP EP99948725A patent/EP1121144B1/en not_active Expired - Lifetime
- 1999-10-15 PT PT99948725T patent/PT1121144E/pt unknown
- 1999-10-15 EP EP01126054A patent/EP1172114B1/en not_active Expired - Lifetime
- 1999-10-15 AU AU61889/99A patent/AU758146B2/en not_active Ceased
- 1999-10-15 DK DK01126054T patent/DK1172114T3/da active
- 1999-10-15 IL IL14201199A patent/IL142011A0/xx active IP Right Grant
- 1999-10-15 BR BR9914585-5A patent/BR9914585A/pt not_active Application Discontinuation
- 1999-10-15 CZ CZ20011134A patent/CZ20011134A3/cs unknown
- 1999-10-15 CA CA002346969A patent/CA2346969A1/en not_active Abandoned
- 1999-10-15 WO PCT/DK1999/000556 patent/WO2000023098A1/en active IP Right Grant
- 1999-10-15 PT PT01126054T patent/PT1172114E/pt unknown
- 1999-10-20 TW TW088118264A patent/TWI223597B/zh not_active IP Right Cessation
-
2001
- 2001-03-14 IL IL142011A patent/IL142011A/en not_active IP Right Cessation
- 2001-03-14 ZA ZA200102105A patent/ZA200102105B/xx unknown
- 2001-04-10 NO NO20011842A patent/NO323365B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0104111A2 (hu) | Stabil, koncentrált inzulinkészítmény pulmonáris bejuttatáshoz | |
| NL300211I1 (nl) | ASP-B28 insulinekristallen. | |
| ES2007607A6 (es) | Un procedimiento para la obtencion de un preparado de insulina para la administracion no parenteral. | |
| HUP0300642A2 (hu) | Antidiabetikus készítmény és alkalmazása | |
| HUP0100243A2 (hu) | Inzulint és/vagy inzulin-analógokat és azok származékait tartalmazó oldhatatlan készítmények, eljárás azok előállítására és alkalmazásuk a vércukor szintjének szabályozására | |
| AU2506388A (en) | Azelastine-containing medicaments for application in the nose and/or at the eye | |
| MX353044B (es) | Liberacion sostenida de anti-infecciosos. | |
| UA34419C2 (uk) | Ліофілізований препарат для ін'єкцій та спосіб інгібування росту пухлин | |
| EP1820862A3 (en) | Medical preparations for the treatment of alpha-galactosidase a deficiency | |
| CA2068324A1 (en) | Metal-peptide compositions and methods for stimulating hair growth | |
| CA2159985A1 (en) | Methods of Using Hesperetin for Sebum Control and Treatment of Acne | |
| AU3927189A (en) | N-2,3-butadienyl tri- and tetraaminoalkane derivatives | |
| DK0402933T3 (da) | Anvendelse af fugtig sucralfatgel som bærer for medikamenter med topisk virkning og for kosmetik | |
| HUP0101914A2 (hu) | L-karnitint vagy alkanoil-L-karnitint és NADH-t és/vagy NADPH-t tartalmazó készítmény | |
| AU6432899A (en) | Use of metformin to counteract weight gain associated with valproate and other psychotropic medications | |
| ZA988820B (en) | Use of delta-aminolaevulinic acid for the preparation of a topical medicament for the integral diagnosis and/or therapy of tumours in hollow organs | |
| HUP0302741A2 (hu) | Fémoxid pigmenteket tartalmazó stabilizált topikális brivudinkészítmények | |
| HUP0100879A2 (hu) | Nukleozidok és alkalmazásuk vírusellenes gyógyszerkészítmények előállítására | |
| CA2041989A1 (en) | Aqueous pharmaceutical formulations of erythropoietin and the use thereof | |
| Nishimura | Pediatric infectious diseases. | |
| RU95105464A (ru) | Противоанемическое средство | |
| GR950100316A (el) | Φαρμακευτικο παρασκευασμα βασιζομενο σε αιωρημα εμβρυικων κυτταρων με δραση ανοσοποιητικης υποκαταστασης και μεθοδος θεραπειας του συνδρομου της επικτητης μολυνσης ανοσοποιητικης ανεπαρκειας (hiv) με τη χρηση αυτου του παρασκευασματος. | |
| RU93032046A (ru) | Способ повышения радиорезистентности организма |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |